Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion

Cancer Letters

Volumn 362, Issue 1, 2015, Pages 97-105

  Leung, Wilson K C ^a   He, Mian ^a   Chan, Anthony W H ^a   Law, Priscilla T Y ^a   Wong, Nathalie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatocellular carcinoma; MiR 182; MiR 183; MiR 96

Indexed keywords

BETA CATENIN; MICRORNA; MICRORNA 182; MICRORNA 183; MICRORNA 96; PROTEIN CTNNB1; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; CTNNB1 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; MIRN182 MICRORNA, HUMAN; MIRN183 MICRORNA, HUMAN; MIRN96 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; RECURRENCE FREE SURVIVAL; TRANSCRIPTION INITIATION; TUMOR DIFFERENTIATION; TUMOR INVASION; UPREGULATION; 3' UNTRANSLATED REGION; BIOSYNTHESIS; CELL MOTION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROGNOSIS; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84931080130     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.023     Document Type: Article

References (36)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Cancer Incidence and Mortality Worldwide 2008, IARC, Lyon. http://globocan.iarc.fr/factsheets/cancers/liver.asp.
2. Poon R.T., Fan S.T. Resection prior to liver transplantation for hepatocellular carcinoma: a strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function. Liver Transpl 2004, 10:813-815.
3. Spizzo R., Nicoloso M.S., Croce C.M., Calin G.A. SnapShot: MicroRNAs in cancer. Cell 2009, 137. 586-586.e1.
4. Budhu A., Jia H.L., Forgues M., Liu C.G., Goldstein D., Lam A., et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897-907.
5. Xiong Y., Fang J.H., Yun J.P., Yang J., Zhang Y., Jia W.H., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010, 51:836-845.
6. Ura S., Honda M., Yamashita T., Ueda T., Takatori H., Nishino R., et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology 2009, 49:1098-1112.
7. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
8. Wong Q.W., Ching A.K., Chan A.W., Choy K.W., To K.F., Lai P.B., et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin. Cancer Res 2010, 16:867-875.
9. Wong Q.W., Lung R.W., Law P.T., Lai P.B., Chan K.Y., To K.F., et al. MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology 2008, 135:257-269.
10. Leung W.K., Ching A.K., Chan A.W., Poon T.C., Mian H., Wong A.S., et al. A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 2011, 30:4464-4475.
11. Cheng A.S., Lau S.S., Chen Y., Kondo Y., Li M.S., Feng H., et al. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res 2011, 71:4028-4039.
12. Wong N., Yeo W., Wong W.L., Wong N.L., Chan K.Y., Mo F.K., et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int. J. Cancer 2009, 123:644-652.
13. Arii S., Okamoto E., Imamura M. Registries in Japan: current status of hepatocellular carcinoma in Japan. Liver Cancer Study Group of Japan. Semin. Surg. Oncol 1996, 12:204-211.
14. Lau H., Fan S.T., Ng I.O., Wong J. Long term prognosis after hepatectomy for hepatocellular carcinoma: a survival analysis of 204 consecutive patients. Cancer 1998, 83:2302-2311.
15. Vauthey J.N., Lauwers G.Y., Esnaola N.F., Do K.A., Belghiti J., Mirza N., et al. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol 2002, 20:1527-1536.
16. Guttilla I.K., White B.A. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J. Biol. Chem 2009, 284:23204-23216.
17. Myatt S.S., Wang J., Monteiro L.J., Christian M., Ho K.K., Fusi L., et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010, 70:367-377.
18. Stittrich A.B., Haftmann C., Sgouroudis E., Kühl A.A., Hegazy A.N., Panse I., et al. The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat. Immunol 2010, 11:1057-1162.
19. Negrini M., Ferracin M., Sabbioni S., Croce C.M. MicroRNAs in human cancer: from research to therapy. J. Cell Sci 2007, 120:1833-1840.
20. Bandrés E., Cubedo E., Agirre X., Malumbres R., Zárate R., Ramirez N., et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol. Cancer 2006, 19:5-29.
21. Lin H., Dai T., Xiong H., Zhao X., Chen X., Yu C., et al. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS ONE 2010, 5. e15797.
22. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 2010, 126:1166-1176.
23. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:1814-1819.
24. Huang H., Regan K.M., Wang F., et al. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:1649-1654.
25. Matsuzaki H., Daitoku H., Hatta M., et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11285-11290.
26. Calvisi D.F., Ladu S., Pinna F., Frau M., Tomasi M.L., Sini M., et al. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis. Gastroenterology 2009, 137:1816-1826.
27. Li W., Tan D., Zhang Z., Liang J.J., Brown R.E. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma. Oncol. Rep 2008, 20:713-719.
28. Chen J.S., Wang Q., Fu X.H., Huang X.H., Chen X.L., Cao L.Q., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res 2009, 39:177-186.
29. Nakanishi K., Sakamoto M., Yamasaki S., Todo S., Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312.
30. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007, 67:2497-2507.
31. Zhang H., Pan Y., Zheng L., Choe C., Lindgren B., Jensen E.D., et al. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion. Cancer Res 2011, 71:3257-3267.
32. Moon R.T., Kohn A.D., De Ferrari G.V., Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet 2004, 5:691-701.
33. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8847-8851.
34. Städeli R., Hoffmans R., Basler K. Transcription under the control of nuclear Arm/beta-catenin. Curr. Biol 2006, 16:R378-R385.
35. Gokhale A., Kunder R., Goel A., Sarin R., Moiyadi A., Shenoy A., et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J. Cancer Res. Ther 2010, 6:521-529.
36. Lai T.Y., Su C.C., Kuo W.W., Yeh Y.L., Kuo W.H., Tsai F.J., et al. β-catenin plays a key role in metastasis of human hepatocellular carcinoma. Oncol. Rep 2011, 26:415-422.